Vaccine Protection After Blinatumomab Treatment in Young People With B-Cell Acute Lymphoblastic Leukemia
Checks whether childhood vaccine protection lasts after blinatumomab in young people with B-ALL.
Plain-language title generated from the registry record
Registry title: A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab
Key facts
- Where
- Little Rock and Springdale, United StatesSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 1 and 23 years old?
Source: NCT07422337, who can take part
Where in United States
- Arkansas Children'sLittle Rock, United StatesTaking people
- Arkansas Children's NorthwestSpringdale, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Arkansas Children's Hospital Research Institute
- Trial code
- NCT07422337
- Record updated
- 28 October 2026
- Original description
The goal of this observational study is to establish a clear vaccination protocol for pediatric patients (less than 21 years old) who have received treatment for B-cell Acute Lymphoblastic Leukemia/Lymphoma. The main study aims are:Read full original descriptionShow less
Blinatumomab's Outcome On Serologic Titers and Efficacy of Revaccination
The goal of this observational study is to establish a clear vaccination protocol for pediatric patients (less than 21 years old) who have received treatment for B-cell Acute Lymphoblastic Leukemia/Lymphoma. The main study aims are:
* Evaluate the persistence of protective immunity to routine childhood vaccinations in participants with B-ALL/Ly who have received blinatumomab. * To determine whether revaccination in participants with non-protective titers leads to restored humoral immunity.
Researchers will compare results from participants who have received immunotherapy to those who have not received immunotherapy to see if immunotherapy versus other chemotherapeutic drugs adversely affect the protective immunity acquired through vaccination.
Inclusion: Diagnosis of B-lineage acute lymphoblastic leukemia/lymphoma; ≥1 year old and up to 21 years old at diagnosis; Informed consent provided, and if applicable, child assent provided; Must have received all vaccinations routinely administered during first year of life.
Exclusion: Received or will require a bone marrow transplant and/or cellular therapy; Relapsed/refractory disease at any time; Pregnancy.